Cancer screening Guardant Health's screening portfolio, including the Shield™ test, targets individuals eligible for cancer screening. This presents a sales opportunity to promote early detection of cancer and personalized treatment plans.

Precision oncology partnerships Guardant Health recently partnered with Hikma Pharmaceuticals PLC to transform cancer care in the Middle East and North Africa. Leveraging such partnerships can open doors for expanding market reach and driving sales in new regions.

Investment influx Baillie Gifford & Co made a significant investment of $167M in Guardant Health. This financial backing indicates investor confidence and potential growth, which can be leveraged to attract more clients and scale operations.

Liquid biopsy innovation Guardant Health's focus on liquid biopsy tests for advanced and early-stage cancer patients showcases a commitment to innovative diagnostic solutions. Highlighting these cutting-edge offerings can appeal to healthcare providers seeking advanced technologies.

Peer-reviewed recognition With over 500 peer-reviewed publications to its credit, Guardant Health has established credibility in the medical community. Leveraging this recognition can support sales efforts by demonstrating the company's expertise and evidence-based solutions.